Collaborative Agreement With Eli Lily and Company for Drug Discovery


Professor Kasturi Haldar, Director for the CRND


(CRND-UND) Has Signed a Collaborative Agreement with Eli Lilly & Company for Drug Discovery and Development for Niemann-Pick Type C, a Rare Disease, and Malaria, a Neglected Disease.

The collaborative agreement negotiated between the CRND and Eli Lilly & Company is a cornerstone for the kind of powerful partnership required to discover, test and bring new therapeutics for rare and neglected diseases to patients. The CRND's overarching mission is to form vibrant relationships between academic researchers, the National Institutes of Health (NIH), major and specialty pharmaceutical companies, funding sources, private donors, and patients in order to focus the synergies of these partnerships with utmost effect and efficiency.

The CRND's catalytic role begins by stimulating early discovery and translational projects at the University of Notre Dame and expands by linking UND's cutting-edge investigators to world-class collaborators and the leaders of industry and government. At the end of 2009, the CRND's Research Incubator Program funded five pioneering proposals for new discovery in Niemann-Pick Type C disease and Malaria. These competitive awards to investigators in UND's Colleges of Engineering and Science launched innovative projects, which promise to excite broad external funding for bench-to-beside development and delivery of diagnostics and therapeutics. CRND also separately supports a Pilot Proteomics Program for biomarker discovery in disease processes and a Clinical Research and Service Program to improve tools to measure disease outcomes in patients.

In November 2009, the CRND Research Incubator Program awardees and others met with Christopher Austin, M.D., Director of the NIH's Chemical Genomics Center. Dr. Austin delivered a CRND Clinical Translational Seminar and explained the extraordinary advances in drug discovery made possible by his institute's Molecular Libraries Probe Production Centers Network (MLCPN). MLPCN's network of small molecule screening centers perform High Throughput Screening for public sector researchers on a scale, which had previously been prohibitive even for giant commercial ventures. The products of early public sector research are made available to the world through PUBCHEM, enabling full-cycle development by venture capital and public sector super funders.

The CRND acknowledges its gratitude to the Ara Parseghian Medical Research Foundation, its collaborators at Eli Lilly & Company and partners at the National Institute of Health. We also acknowledge an extraordinary network of collaborators world-wide and on-campus (the Offices of Research and Sponsored Programs, Office of General Counsel, Office of Development, The Advanced Diagnostics and Therapeutics Initiative, the ECK Institute of Global Health, the Notre Dame Haiti Program, the Ford Program in Human Development Studies and Solidarity, the Center for Social Concerns, the Chemistry Synthesis Initiative, the Center for Research Computing, and the Colleges of Science, Engineering, and Arts and Letters). We thank the University of Notre Dame for its enduring support.




Of Interest...